GUTS FRACTYL HEALTH, INC.

BULLISH Impact: 6/10 8-K
Horizon months Filed Jun 4, 2026 Processed 8d 21h ago SEC 0001193125-26-256445
8-K context-dependent: Items 7.01, 8.01
Latest settled — T+1d ⚠ clustered
GUTS ▼ -7.49% at T+1d
LONG call ✗ call lost -7.49% · α vs SPY -4.89% · entry $0.7340 → $0.6790
Next anchor: T+5d due yesterday
Currently $0.8500 · +15.80% from $0.7340 entry
Entry anchored
Jun 4, 2026
via day open
T+1d
-7.49%
call -7.49% · α -4.89%
$0.6790
settled 8d ago
T+5d
call — · α —
due yesterday
T+20d
call — · α —
in 20d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Fractyl Health reported positive one-year open-label results from the REVEAL-1 cohort, showing that a single Revita procedure allowed patients to maintain ~78% of prior GLP-1-induced weight loss at one year, with 33% continuing to lose weight and no serious adverse events. This de-risks Revita's potential as a post-GLP-1 weight maintenance therapy ahead of pivotal REMAIN-1 data in Q3/Q4 2026.

Actionable Insight

The strong durability signal from REVEAL-1 supports Revita's differentiation; watch for REMAIN-1 randomized data in Q3/Q4 2026 as the next major catalyst. Given small sample size and open-label design, confirmatory pivotal data will be critical for sustained upside.

Key Facts

  • Participants retained ~78% of prior GLP-1-induced weight loss at one year after a single Revita procedure (n=15).
  • 33% of patients continued to lose weight one year after discontinuing GLP-1.
  • Mean total body weight change was 5.3% (LS mean) at one year; comparator GLP-1 withdrawal shows ~15% weight regain.
  • No procedure-related serious adverse events; mild transient events in 36% of participants.
  • Next data readouts: REMAIN-1 Midpoint Cohort in Q3 2026 and REMAIN-1 Pivotal Cohort in early Q4 2026.

Financial Impact

This is a clinical-stage company with no revenue; the positive data could significantly impact valuation if pivotal trials succeed.

Risk Factors

  • Open-label, single-arm design with small sample size (n=15 efficacy dataset) limits statistical robustness.
  • Five participants withdrew or were lost to follow-up, potentially introducing bias.
  • Regulatory and commercial adoption risks remain; rejection of Revita in pivotal trials would reset expectations.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-256445
Document: guts-ex99_1.htm0001193125-26-256445
Document: 0001193125-26-256445-index-headers.html0001193125-26-256445
Document: 0001193125-26-256445-index.html0001193125-26-256445
Document: 0001193125-26-256445.txt0001193125-26-256445
12 reports for GUTS
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+5▲ +4.81%May 11, 2026
Filters
Rows
Reports for GUTS — sortable, filterable
Type Now
Jun 12, 2026
today
Institutional Cluster
MIXED ★ 4/10
$0.7265 awaiting T+1awaiting T+1$0.8500 (+17.00%)
Jun 11, 2026
1d ago
Insider Cluster
NEUTRAL ★ 3/10
$0.7265 awaiting T+1awaiting T+1$0.8500 (+17.00%)
Jun 11, 2026
1d ago
Institutional Cluster
NEUTRAL ★ 3/10
$0.7200 awaiting T+1awaiting T+1$0.8500 (+18.06%)
Jun 4, 2026
8d ago
8-K
BULLISH ★ 6/10
$0.7340 $0.6790▼ −7.49%▼ −4.89%$0.8500 (+15.80%)
Jun 4, 2026
8d ago
Press Release
BULLISH ★ 7/10
$0.7340 $0.6790▼ −7.49%▼ −4.89%$0.8500 (+15.80%)
May 12, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$0.9480 $0.9480· 0.00%▲ +0.00%$0.8500 (−10.34%)
May 12, 2026
4w ago
Press Release
NEUTRAL ★ 4/10
$0.9480 $0.9480· 0.00%▲ +0.00%$0.8500 (−10.34%)
May 11, 2026
4w ago
8-K
BULLISH ★ 5/10
$0.7690 $0.7340▼ −4.55%▼ −4.41%$0.8500 (+10.53%)
May 11, 2026
4w ago
Press Release
BULLISH ★ 7/10
$0.7690 $0.7340▼ −4.55%▼ −4.41%$0.8500 (+10.53%)
Apr 24, 2026
7w ago
DEFA14A
NEUTRAL ★ 2/10
$0.6530 $0.6560▲ +0.46%▲ +0.94%$0.8500 (+30.17%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (53h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access